Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
Submitted by
admin
on June 4, 2018 - 9:16am
Source:
CP Wire
News Tags:
Array Biopharma
encorafenib
binimetinib
advanced melanoma
ASCO 2018
Headline:
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
snippet:
Median overall survival for combination 33.6 months vs 16.9 for control
Two year overall survival was 58%
Results selected for “Best of ASCO” program
Do Not Allow Advertisers to Use My Personal information
